8-K: Surrozen Announces Fourth Quarter and Full Year 2024 Financial Results and Business Updates

Surrozen, Inc. reported its financial results for the fourth quarter and full year 2024, highlighting progress in its ophthalmology pipeline and a recent financing.

Summary

• Surrozen, Inc. released its financial results for the fourth quarter and full year 2024.
• The company is prioritizing its ophthalmology pipeline programs.
• Surrozen completed the first closing of a two-tranche financing of $175 million in aggregate gross proceeds.
• Cash and cash equivalents were $34.6 million as of December 31, 2024, compared to $36.0 million as of December 31, 2023.
• Collaboration and license revenue for the full year 2024 was $10.0 million, compared to zero in 2023, due to a milestone achieved with Boehringer Ingelheim (BI).
• Research service revenue from a related party was $0.7 million for the full year 2024, compared to zero in 2023, related to services provided to TCGFB, Inc.
• Research and development expenses for the full year 2024 were $21.1 million, compared to $27.2 million in 2023.
• General and administrative expenses for the full year 2024 were $15.1 million, compared to $15.8 million in 2023.
• Net loss for the full year 2024 was $63.6 million, compared to $43.0 million in 2023.
• The company is developing SZN-8141 and SZN-8143 for retinal diseases, combining Fzd4 agonism and VEGF antagonism.
• SZN-413 is being developed for the treatment of retinal vascular-associated diseases.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the company is making progress in its ophthalmology pipeline and secured significant financing, the increased net loss and slight decrease in cash position temper the positive aspects.

Positives

• Surrozen is prioritizing its ophthalmology pipeline, which has the potential to provide new treatment options.
• The $175 million financing will fund multiple ophthalmology programs through Phase 1 studies.
• Collaboration and license revenue increased to $10.0 million in 2024 due to a milestone achieved with BI.
• Research and development expenses decreased due to restructuring and discontinuation of SZN-1326 development.

Negatives

• The company experienced a net loss of $63.6 million for the full year 2024, which is higher than the $43.0 million loss in 2023.
• Other expenses increased significantly due to the non-cash change in fair value of warrant liabilities.
• Cash and cash equivalents decreased slightly from $36.0 million at the end of 2023 to $34.6 million at the end of 2024.

Risks

• The company's ability to successfully complete preclinical and clinical studies for its product candidates is subject to risks and uncertainties.
• The company's ability to fund its preclinical and clinical trials and development efforts, whether with existing funds or through additional fundraising, is a risk.
• Volatility in global economic, political, regulatory, and market conditions could negatively impact the company.

Future Outlook

The company will focus its Wnt biology expertise and Wnt signal modulation antibody technologies on its ophthalmology programs, including development of new treatment options for retinopathies. The $175 million financing will fund multiple ophthalmology programs through Phase 1 safety, tolerability and efficacy studies.

Management Comments

• Craig Parker, President and Chief Executive Officer of Surrozen, stated that the company continued to leverage its research capabilities and expertise in antibody engineering technologies focused on Wnt signal modulation.
• Craig Parker mentioned the private financing to advance the novel ophthalmology-focused pipeline toward the clinic.

Industry Context

Surrozen's focus on ophthalmology and Wnt pathway modulation aligns with the growing interest in targeted therapeutics for tissue repair and regeneration. The development of SZN-8141, SZN-8143, and SZN-413 addresses the need for improved treatment options for retinal diseases, where current standards of care often involve anti-VEGF monotherapies.

Comparison to Industry Standards

• Surrozen's approach of combining Fzd4 agonism and VEGF antagonism in SZN-8141 and SZN-8143 is innovative compared to standard anti-VEGF monotherapies used by companies like Regeneron (Eylea) and Novartis (Lucentis).
• The development of SZN-413 using Surrozen's SWAP technology for retinal vascular-associated diseases positions the company to compete with other companies developing novel biologics for eye diseases, such as Roche (Vabysmo).
• The $175 million financing provides Surrozen with capital to advance its ophthalmology programs, which is comparable to funding rounds for other biotech companies in the early stages of clinical development, such as those seen by companies like Kodiak Sciences and Ocular Therapeutix.

Related Party Transactions

• Research service revenue related to TCGFB, Inc. under the research collaboration agreement was $0.7 million for the full year 2024.

Stakeholder Impact

• Shareholders may be concerned about the increased net loss, but encouraged by the focus on ophthalmology and the recent financing.
• Employees may benefit from the company's focus on ophthalmology and the funding for research and development.
• The company's ophthalmology programs have the potential to provide new treatment options for patients with severe eye diseases.

Next Steps

• Advance ophthalmology programs through Phase 1 safety, tolerability, and efficacy studies.
• Further develop SZN-413 for the treatment of retinal vascular-associated diseases.
• Continue research and development activities focused on Wnt signal modulation.

Key Dates

Keywords

Surrozen, financial results, ophthalmology, Wnt pathway, retinal diseases, SZN-8141, SZN-8143, SZN-413, financing, biotechnology